Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Terns Pharmaceuticals launched with $30mm Series A from Lilly Asia

Executive Summary

Terns Pharmaceuticals Inc. raised $30mm in Series A funding from Lilly Asia Ventures. The company was recently launched and is developing molecularly-targeted oral small-molecule candidates for liver diseases (including nonalcoholic steatohepatitis) and cancer. Terns is based in California and Shanghai, and intends to initially focus its drug development efforts on unmet medical needs in China.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register